RSS feed

Publications by Gisle Langslet

68 publications found

Original articles

Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF et al. (2023)
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Cardiovasc Diabetol, 22 (1), 233
DOI 10.1186/s12933-023-01963-9, PubMed 37653496

Johansen AK, Bogsrud MP, Christensen JJ, Rundblad A, Narverud I, Ulven S, Langslet G, Retterstøl K, Holven KB (2023)
Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: Novel data using repeated measurements during 12-years follow-up
Atheroscler Plus, 51, 28-34
DOI 10.1016/j.athplu.2023.01.001, PubMed 36911286

Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G et al. (2023)
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab, 49 (2), 101418
DOI 10.1016/j.diabet.2022.101418, PubMed 36608816

Langslet G, Johansen AK, Bogsrud MP, Narverud I, Risstad H, Retterstøl K, Holven KB (2021)
Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues
Am J Prev Cardiol, 6, 100180
DOI 10.1016/j.ajpc.2021.100180, PubMed 34327501

Arnesen KE, Phung AV, Randsborg K, Mork I, Thorvall M, Langslet G, Svilaas A, Wium C, Ose L, Retterstøl K (2021)
Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study
Front Pharmacol, 11, 560958
DOI 10.3389/fphar.2020.560958, PubMed 33737874

Johansen AK, Bogsrud MP, Roeters van Lennep J, Narverud I, Langslet G, Retterstøl K, Holven KB (2021)
Long term follow-up of children with familial hypercholesterolemia and relatively normal LDL-cholesterol at diagnosis
J Clin Lipidol, 15 (2), 375-378
DOI 10.1016/j.jacl.2021.01.007, PubMed 33608220

Hovland A, Narverud I, Lie Øyri LK, Bogsrud MP, Aagnes I, Ueland T, Mulder M, Leijten F, Langslet G, Wium C, Svilaas A, Arnesen KE, Roeters van Lennep J, Aukrust P, Halvorsen B, Retterstøl K, Holven KB (2020)
Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers
J Clin Lipidol, 15 (1), 134-141
DOI 10.1016/j.jacl.2020.12.006, PubMed 33358307

Svendsen K, Langslet G, Krogh HW, Brinck J, Klausen IC, Stenehjem JS, Holven KB, Bogsrud MP, Retterstøl K (2020)
Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia
Atherosclerosis, 316, 48-52
DOI 10.1016/j.atherosclerosis.2020.11.027, PubMed 33302044

Langslet G, Hovingh GK, Guyton JR, Baccara-Dinet MT, Letierce A, Manvelian G, Farnier M (2020)
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
Cardiovasc Drugs Ther, 34 (4), 515-523
DOI 10.1007/s10557-020-06984-0, PubMed 32363493

Langslet G, Zinman B, Wanner C, Hantel S, Espadero RM, Fitchett D, Johansen OE (2020)
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME^®
Diab Vasc Dis Res, 17 (6), 1479164120975256
DOI 10.1177/1479164120975256, PubMed 33307785

Müller-Wieland D, Rader DJ, Moriarty PM, Bergeron J, Langslet G, Ray KK, Manvelian G, Thompson D, Bujas-Bobanovic M, Roth EM (2019)
Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
J Clin Endocrinol Metab, 104 (11), 5253-5262
DOI 10.1210/jc.2018-02703, PubMed 31166599

Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJ (2019)
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
J Am Coll Cardiol, 74 (17), 2132-2146
DOI 10.1016/j.jacc.2019.08.1024, PubMed 31648705

Bogsrud MP, Græsdal A, Johansen D, Langslet G, Hovland A, Arnesen KE, Mundal LJ, Retterstøl K, Wium C, Holven KB (2019)
LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia
J Clin Lipidol, 13 (2), 279-286
DOI 10.1016/j.jacl.2019.01.010, PubMed 30910667

Urke EB, Søbye S, Ellingvåg A, Langslet G, Retterstøl K, Wandel M (2018)
Familial hypercholesterolemia and young patients' thoughts on own condition and treatment
Patient Educ Couns, 102 (5), 1005-1012
DOI 10.1016/j.pec.2018.12.025, PubMed 30606641

Dufour R, Hovingh GK, Guyton JR, Langslet G, Baccara-Dinet MT, Din-Bell C, Manvelian G, Farnier M (2018)
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial
J Clin Lipidol, 13 (1), 138-147
DOI 10.1016/j.jacl.2018.11.007, PubMed 30591415

Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Guyton JR (2018)
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
Atherosclerosis, 278, 307-314
DOI 10.1016/j.atherosclerosis.2018.08.036, PubMed 30293878

McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH (2018)
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)
Am J Cardiol, 121 (8), 940-948
DOI 10.1016/j.amjcard.2017.12.040, PubMed 29472008

Gaudet D, Langslet G, Gidding SS, Luirink IK, Ruzza A, Kurtz C, Lu C, Somaratne R, Raal FJ, Wiegman A (2018)
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study
J Clin Lipidol, 12 (5), 1199-1207
DOI 10.1016/j.jacl.2018.05.007, PubMed 30318065

Holven KB, Narverud I, van Lennep JR, Versmissen J, Øyri LKL, Galema-Boers A, Langslet G, Ulven SM, Veierød MB, Retterstøl K, Bogsrud MP (2018)
Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH
J Clin Lipidol, 12 (3), 748-755.e2
DOI 10.1016/j.jacl.2018.02.021, PubMed 29609857

Hovingh GK, Guyton JR, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Farnier M (2018)
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia
J Clin Lipidol, 12 (6), 1463-1470
DOI 10.1016/j.jacl.2018.08.011, PubMed 30287210

Hartgers ML, Defesche JC, Langslet G, Hopkins PN, Kastelein JJP, Baccara-Dinet MT, Seiz W, Hamon S, Banerjee P, Stefanutti C (2017)
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
J Clin Lipidol, 12 (2), 390-396.e8
DOI 10.1016/j.jacl.2017.12.008, PubMed 29396260

Bogsrud MP, Langslet G, Wium C, Johansen D, Svilaas A, Holven KB (2017)
Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway
J Clin Lipidol, 12 (2), 375-382
DOI 10.1016/j.jacl.2017.11.009, PubMed 29310990

Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Kusters DM, Raichlen JS, Martin PD, Stein EA, Kastelein JJP, Hutten BA (2017)
Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)
Circulation, 136 (4), 359-366
DOI 10.1161/CIRCULATIONAHA.116.025158, PubMed 28592434

Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ (2017)
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
JAMA Cardiol, 2 (6), 598-607
DOI 10.1001/jamacardio.2017.0747, PubMed 28291870

Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, Hamon SC, Banerjee P, Kastelein JJP (2017)
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia
J Clin Lipidol, 11 (6), 1338-1346.e7
DOI 10.1016/j.jacl.2017.08.016, PubMed 28964736

Kastelein JJ, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, Zhao J, Minini P, Farnier M (2016)
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
J Clin Lipidol, 11 (1), 195-203.e4
DOI 10.1016/j.jacl.2016.12.004, PubMed 28391886

Roth EM, Moriarty PM, Bergeron J, Langslet G, Manvelian G, Zhao J, Baccara-Dinet MT, Rader DJ, ODYSSEY CHOICE I investigators (2016)
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Atherosclerosis, 254, 254-262
DOI 10.1016/j.atherosclerosis.2016.08.043, PubMed 27639753

Leiter LA, Langslet G, Vijapurkar U, Davies MJ, Canovatchel W (2016)
Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin
Diabetes Ther, 7 (2), 269-78
DOI 10.1007/s13300-016-0163-1, PubMed 26984361

Langslet G, Breazna A, Drogari E (2016)
A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia
J Clin Lipidol, 10 (5), 1153-1162.e3
DOI 10.1016/j.jacl.2016.05.010, PubMed 27678432

Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M (2015)
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
Eur Heart J, 36 (43), 2996-3003
DOI 10.1093/eurheartj/ehv370, PubMed 26330422

Braamskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegman A, Hounslow N, Kastelein JJ, PASCAL Study Group (2015)
Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk
J Pediatr, 167 (2), 338-43.e5
DOI 10.1016/j.jpeds.2015.05.006, PubMed 26059337

Schernthaner G, Durán-Garcia S, Hanefeld M, Langslet G, Niskanen L, Östgren CJ, Malvolti E, Hardy E (2015)
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
Diabetes Obes Metab, 17 (7), 630-8
DOI 10.1111/dom.12461, PubMed 25761977

Langslet G, Emery M, Wasserman SM (2015)
Evolocumab (AMG 145) for primary hypercholesterolemia
Expert Rev Cardiovasc Ther, 13 (5), 477-88
DOI 10.1586/14779072.2015.1030395, PubMed 25824308

Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators (2015)
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
N Engl J Med, 372 (16), 1489-99
DOI 10.1056/NEJMoa1501031, PubMed 25773378

Kastelein JJ, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y (2015)
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
Lancet, 385 (9983), 2153-61
DOI 10.1016/S0140-6736(14)62115-2, PubMed 25743173

Langslet G, Bogsrud MP, Halvorsen I, Fjeldstad H, Retterstøl K, Veierød MB, Ose L (2015)
Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood
J Clin Lipidol, 9 (6), 778-785
DOI 10.1016/j.jacl.2015.08.008, PubMed 26687698

Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagné C, Gaudet D, Morrison KM, Wiegman A, Turner T, Kusters DM, Miller E, Raichlen JS, Wissmar J, Martin PD, Stein EA, Kastelein JJP (2015)
Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
J Clin Lipidol, 9 (6), 741-750
DOI 10.1016/j.jacl.2015.07.011, PubMed 26687694

Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D, RUTHERFORD-2 Investigators (2014)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Lancet, 385 (9965), 331-40
DOI 10.1016/S0140-6736(14)61399-4, PubMed 25282519

Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, Millington D, Vercruysse F, Canovatchel W, Meininger G (2014)
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study
Diabetes Care, 38 (3), 355-64
DOI 10.2337/dc13-2762, PubMed 25205142

Versmissen J, Oosterveer DM, Yazdanpanah M, Dehghan A, Hólm H, Erdman J, Aulchenko YS, Thorleifsson G, Schunkert H, Huijgen R, Vongpromek R, Uitterlinden AG, Defesche JC, van Duijn CM, Mulder M, Dadd T, Karlsson HD, Ordovas J, Kindt I, Jarman A, Hofman A, van Vark-van der Zee L, Blommesteijn-Touw AC, Kwekkeboom J, Liem AH et al. (2014)
Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach
Eur J Hum Genet, 23 (3), 381-7
DOI 10.1038/ejhg.2014.101, PubMed 24916650

Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, Gipe DA, Baccara-Dinet MT (2014)
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies
Cardiovasc Drugs Ther, 28 (3), 281-9
DOI 10.1007/s10557-014-6523-z, PubMed 24842558

Sjouke B, Langslet G, Ceska R, Nicholls SJ, Nissen SE, Öhlander M, Ladenson PW, Olsson AG, Hovingh GK, Kastelein JJ (2014)
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
Lancet Diabetes Endocrinol, 2 (6), 455-63
DOI 10.1016/S2213-8587(14)70006-3, PubMed 24731671

Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA (2014)
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials
J Am Coll Cardiol, 63 (13), 1278-1288
DOI 10.1016/j.jacc.2014.01.006, PubMed 24509273

Holven KB, Narverud I, Lindvig HW, Halvorsen B, Langslet G, Nenseter MS, Ulven SM, Ose L, Aukrust P, Retterstøl K (2014)
Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment
Atherosclerosis, 233 (2), 561-567
DOI 10.1016/j.atherosclerosis.2014.01.022, PubMed 24530965

Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS, OSLER Investigators (2013)
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial
Circulation, 129 (2), 234-43
DOI 10.1161/CIRCULATIONAHA.113.007012, PubMed 24255061

Bogsrud MP, Langslet G, Ose L, Arnesen KE, Sm Stuen MC, Malt UF, Woldseth B, Retterstøl K (2013)
No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy
Scand Cardiovasc J, 47 (2), 80-7
DOI 10.3109/14017431.2012.756119, PubMed 23301875

Kusters DM, Hutten BA, McCrindle BW, Cassiman D, Francis GA, Gagné C, Gaudet D, Morrison KM, Langslet G, Kastelein JJ, Wiegman A (2013)
Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia
J Clin Lipidol, 7 (5), 408-13
DOI 10.1016/j.jacl.2013.06.010, PubMed 24079281

Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, Brekke M, Retterstøl K, Arnesen KE, Ose L (2012)
Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia
J Clin Lipidol, 6 (4), 331-9
DOI 10.1016/j.jacl.2012.03.004, PubMed 22836070

Nenseter MS, Lindvig HW, Ueland T, Langslet G, Ose L, Holven KB, Retterstøl K (2011)
Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia
Atherosclerosis, 216 (2), 426-32
DOI 10.1016/j.atherosclerosis.2011.02.007, PubMed 21376325

Langslet G, Ottestad I, Retterstøl K, Ose L (2010)
[Clinical trials--viewpoints from participants]
Tidsskr Nor Laegeforen, 130 (16), 1606-8
DOI 10.4045/tidsskr.09.0030, PubMed 20805857

Bogsrud MP, Ose L, Langslet G, Ottestad I, Strøm EC, Hagve TA, Retterstøl K (2010)
HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study
Scand Cardiovasc J, 44 (4), 197-200
DOI 10.3109/14017431003624123, PubMed 20636227

Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, Hsia J, Kastelein JJ, Stein EA (2010)
Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia
J Am Coll Cardiol, 55 (11), 1121-6
DOI 10.1016/j.jacc.2009.10.042, PubMed 20223367

Review articles

Svilaas T, Klemsdal TO, Bogsrud MP, Græsdal A, Vesterbekkmo EK, Asprusten EA, Langslet G, Retterstøl K (2022)
High levels of lipoprotein(a) - assessment and treatment
Tidsskr Nor Laegeforen, 142 (1)
DOI 10.4045/tidsskr.21.0800, PubMed 36655975

Atar D, Langslet G, Tonstad S (2022)
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Kardiol Pol, 80 (7-8), 741-749
DOI 10.33963/KP.a2022.0117, PubMed 35521719

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
Heart Fail Rev, 23 (3), 303-323
DOI 10.1007/s10741-018-9685-0, PubMed 29516230

Langslet G, Ose L (2013)
Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia
Expert Rev Cardiovasc Ther, 11 (8), 1061-6
DOI 10.1586/14779072.2013.814851, PubMed 23984929

Langslet G, Reikvam A (2008)
[Can cardiovascular events be prevented by raising HDL cholesterol?]
Tidsskr Nor Laegeforen, 128 (13), 1519-23
PubMed 18587459

Other articles

Langslet G (2023)
Is prediabetes a cardiovascular risk factor in patients with coronary artery disease?
Eur J Prev Cardiol, 30 (14), 1416-1417
DOI 10.1093/eurjpc/zwad097, PubMed 37036914

Langslet G (2023)
Dairy fat and cardiovascular disease: good or bad? A lipidologist's view
Eur J Prev Cardiol, 30 (3), 217-218
DOI 10.1093/eurjpc/zwac244, PubMed 36315006

Svilaas T, Klemsdal TO, Bogsrud MP, Græsdal A, Vesterbekkmo EK, Asprusten EA, Langslet G, Retterstøl K (2023)
[Correction: High levels of lipoprotein(a) – assessment and treatment]
Tidsskr Nor Laegeforen, 143 (2)
DOI 10.4045/tidsskr.23.0023, PubMed 36718898

Langslet G, Holven KB, Bogsrud MP (2022)
Treatment goals in familial hypercholesterolaemia-time to consider low-density lipoprotein-cholesterol burden
Eur J Prev Cardiol, 29 (17), 2278-2280
DOI 10.1093/eurjpc/zwab228, PubMed 34935933

Hovingh GK, Klausen IC, Heggen E, McCarty K, Zhou R, Isaac BF, Taub R, Langslet G, Kastelein JJP (2022)
Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia
J Am Coll Cardiol, 79 (12), 1220-1222
DOI 10.1016/j.jacc.2022.01.023, PubMed 35331419

Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, Hamon SC, Banerjee P, Kastelein JJP (2020)
Corrigendum to "Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia" J Clin Lipidol 11 (2017) 1338-1346
J Clin Lipidol, 14 (5), 742
DOI 10.1016/j.jacl.2020.09.010, PubMed 33138962

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
Author's response to: letter to the editor
Heart Fail Rev, 23 (5), 819
DOI 10.1007/s10741-018-9728-6, PubMed 30043131

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
Response to the editor
Heart Fail Rev (in press)
DOI 10.1007/s10741-018-9723-y, PubMed 29968222

Kusters DM, Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Raichlen J, Martin PD, Stein EA, Kastelein JJP, Hutten BA (2018)
Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)"
Circulation, 137 (6), 641-642
DOI 10.1161/CIRCULATIONAHA.117.031676, PubMed 29431667

Langslet G, Bogsrud MP, Wium C, Johansen D, Svilaas A, Holven KB (2018)
Some children with a familial hypercholesterolemia mutation may exhibit persistent low LDL levels
J Clin Lipidol, 12 (5), 1327-1328
DOI 10.1016/j.jacl.2018.06.012, PubMed 30033003

Langslet G (2016)
Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea
Eur Heart J, 37 (17), 1357-9
DOI 10.1093/eurheartj/ehw098, PubMed 27026748